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DPPGAbstract Ehrlich tumors were grown in female balb mice by subcutaneous injection of Ehrlich asci-
tes carcinoma cells. Mice bearing Ehrlich tumor were injected with saline, DOX in solution or DOX
encapsulated within liposomes prepared from DMPC/CHOL/DPPG/PEG-PE (100:100:60:4) in
molar ratio. Cytotoxicity assay showed that the IC50 of liposomes containing DOXwas greater than
that DOX only. Tumor growth inhibition curves in terms of mean tumor size (cm3) were presented.
All the DOX formulations were effective in preventing tumor growth compared to saline. Treatment
with DOX loaded liposomes displayed a pronounced inhibition in tumor growth than treatment with
DOX only. Histopathological examination of the entire tumor sections for the various groups
revealed marked differences in cellular features accompanied by varying degrees in necrosis percent-
age ranging from 12% for saline treated mice to 70% for DOX loaded liposome treated mice. The
proposed liposomal formulation can efﬁciently deliver the drug into the tumor cells by endocytosis
(or passive diffusion) and lead to a high concentration of DOX in the tumor cells. The study showed
that the formulation of liposomal doxorubicin improved the therapeutic index of DOX and had
increased anti-tumor activity against Ehrlich tumor models.
ª 2014 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Anthracycline-based antibiotics such as doxorubicin (DOX),
pirarubicin and daunorubicin have found widespread applica-tion in cancer chemotherapy. DOX is an anthracycline com-
monly used to treat several solid tumors, acute leukemia and
malignant lymphoma (Kawano et al., 2003; Daemen et al.,
1997; Mady et al., 2012). DOX can inhibit the replication pro-
cess of cells by crossing the tumor cellular membrane and inter-
calating into the base pairs of DNA (Shi et al., 1993). However,
severe clinical side effects, such as cardiotoxicity and myelosup-
pression, are of major concern. The prevailing liposomal drug
delivery system can provide a solution to this problem.
Three basic requirements need to be fulﬁlled if liposomes are
to be successful in delivering drugs speciﬁcally to cancerous tis-
sue: (i) prolonged blood circulation, (ii) sufﬁcient tumor accu-
mulation, (iii) controlled drug release and uptake by tumor
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the drug. Passive targeting can result in increases in drug concen-
trations in solid tumors of several-fold relative to those obtained
with free drugs (Rahman et al., 1986; Sapra and Allen, 2003).
The mechanism of action of the liposomal drugs is thought to
be due to sustained release of drug from the liposomes and diffu-
sion of the released drug throughout the tumor interstitial ﬂuid,
with subsequent uptake of the released drug by tumor cells.
However, liposomes have been found to be plagued by rapid
opsonization and by their being taken up by the reticuloendo-
thelial system (RES) cells located mainly in the liver and spleen.
In general, this rapid uptake of the liposomes leads to their hav-
ing a short circulation time. This problem has been resolved by
incorporating lipid-grafted polyethyleneglycol (PEG) into the
liposome membrane. The incorporation of lipid-grafted PEG
reportedly reduced the opsonization of the liposomes and conse-
quently increased their circulation time (Allen et al., 1991;
Papahadjopoulos et al., 1991; Mercadal et al., 1999; Lu et al.,
2004).
PEG liposomal DOX has revealed an increased therapeutic
efﬁcacy and reduced cardiotoxicity compared to free DOX
(Gabizon et al., 2003; Ogawara et al., 2008). However, there
is little information on the therapeutic efﬁcacy of PEG liposo-
mal DOX in multidrug-resistant tumor-bearing animal model.
Generally, chemotherapeutic drugs are administered to
cancer patients for a long term with low dosage to prevent
severe side effects, which often causes the cancer cells to
acquire the resistance against the chemotherapeutic drug and
the effectiveness of the drug gradually decreases. Resistance
acquisition of the cancer cells by long-term exposure of the
chemotherapeutic drugs, called ‘‘multidrug resistance’’, has
been considered as a major obstacle in the current clinical can-
cer chemotherapy (Chung et al., 1997).
Therefore, in order to improve the entrapment efﬁciency,
we investigated a new liposomal composition of DMPC/
CHOl/DPPG/PEG (100:100:60:4) in molar ratio. As the chem-
ical composition, charge, structure and mode of preparation
are all known variables that can modify the physicochemical,
biological and pharmacological properties of the liposomes
and therefore of the encapsulated drug, the present study
was undertaken to evaluate the new liposomal doxorubicin
formulation for its modulation of efﬁcacy and pharmacoki-
netic behavior in Ehrlich tumor bearing mice.
However, except for the limited number of successful
approaches that have launched into the clinical trial (Barraud
et al., 2005), the outcomes from most of the approaches espe-
cially in the in vivo studies have been found to be still unsatis-
factory to overcome the multidrug resistance of cancer cells.
The present study was undertaken to evaluate a new liposo-
mal doxorubicin formulation, composed of DMPC/CHOL/
DPPG/PEG and summarized that DOX loaded liposomes
were able to enhance the intracellular uptake of the entrapped
DOX by HCT-15 cells and improve the therapeutic efﬁcacy of
Ehrlich carcinoma treatment.
2. Materials and methods
2.1. Materials
1,2-Dipalmitoyl-sn-glycero-3-phosphoglycerol, (DPPG), L-a-
dimyristoyl phosphatidyl-choline (DMPC) lipid andcholesterol (CHOL) type 99% pure were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). Distearoyl phos-
phatidylethanolamine derivatized at the amino position with
2000 molecular weight segment of poly (-ethylene glycol),
PEG-PE, was obtained from Calbiochem (La Jolla, CA). Adri-
blastina that consists of DOX hydrochloride was obtained
from Pharmacia Italia, SPA, Italy. Dimethylsulfoxide
(DMSO), RPMI-1640 medium, Sodium bicarbonate, Trypan
blue, Fetal Bovine Serum, Penicillin/Streptomycin, Trypsin,
Acetic acid, Sulforhodamine-B (SRB) and Trichloroacetic acid
(TCA) were obtained from Sigma Chemical Co., St. Louis,
Mo, U.S.A. Chloroform (CHCl3) was purchased from Sigma
Aldrich (St. Louis, MO, USA). All other reagent and solvents
were of analytical grade and were used without further
puriﬁcation.
2.2. Liposomal preparation
We prepared multilamellar vesicles (MLV) of DMPC/CHOL/
DPPG/PEG-PE (100:100:60:4) in molar ratio, according to
the reverse phase evaporation method (Szoka and
Papahadjopoulos, 1978). The lipids were ﬁrst dissolved and
mixed in chloroform to ensure a homogeneous mixture of lip-
ids. The organic solvent was removed by rotary evaporation
to yield a thin lipid ﬁlm on the sides of a round bottom ﬂask.
Hydration of the dry lipid ﬁlm was accomplished by simply
adding deionized water to the container of dry lipid and agi-
tating at a temperature greater than the phase transition tem-
perature of the lipid. The ﬁnal lipid concentration was 5 mg/
ml. The resulting lipid suspension was extruded through
200 nm polycarbonate membranes (Nucleopore GmbH, Ger-
many), using a commercially available extruder LiposoFast,
Avestin Inc., Canada). Size measurement was done by
dynamic laser light scattering (Zetasizer 3000 HS, Malvern
Instruments, Germany) and the size was in the range of
200 ± 30 nm. For the DOX liposomal sample, hydration of
the dry lipid thin ﬁlm was achieved with 2 ml of deionized
water containing DOX (5 mg/ml). The ﬂask was mechanically
shaken for 15 min at 45 C. The suspension was then centri-
fuged at 13,000 rpm three times for 15 min each to remove
non-encapsulated drug.
2.3. Cell culture and inoculation of mice with tumor cells
Ehrlich ascites tumor was chosen as a rapidly growing exper-
imental tumor model where various experimental designs for
anticancer agents can be applied (Elbialy et al., 2010). Ehrlich
ascites carcinoma cells (1 · 106 cells) obtained from the
National Cancer Institute ‘‘NCI’’-Cairo University, were
intraperitoneally injected into female balb mice. Ascites ﬂuid
was collected on the 7th day after injection. The Ehrlich cells
were washed twice and then resuspended in 5 ml saline.
Female balb mice of 22–25 g body weight and 6–8 weeks old
(obtained from the animal house of NCI) were then injected
subcutaneously in their right ﬂanks where the tumors were
developed in a single and solid form. Tumor growth was mon-
itored post-inoculation until the desired volume was about
0.3–0.6 cm3. All animal procedures and care were performed
using guidelines for the Care and Use of Laboratory Animals
and approved by the Animal Ethics Committee at Cairo
University.
184 N.S. Elbialy, M.M. Mady2.4. Sulforhodamine-B (SRB) assay of cytotoxic activity
The sensitivity of the human tumor cell lines to thymoqui-
none was determined by the SRB assay. SRB is a bright pink
aminoxanthrene dye with two sulfonic groups. It is a protein
stain that binds to the amino groups of intracellular proteins
under mildly acidic conditions to provide a sensitive index of
cellular protein content. HCT-15 (colon cancer cell line) cells
were seeded in 96-well microtiter plates at a concentration of
5 · 104–105 cell/well in a fresh medium and left to attach to
the plates for 24 h. After 24 h, cells were incubated with
DOX and DOX loaded liposome samples, completed to total
of 200 ll volume/well using fresh medium and incubation was
continued for 48. Following 48 h treatment, the cells were
ﬁxed with 50 ll cold 50% trichloroacetic acid for 1 h at
4 C. Wells were washed 5 times with distilled water and
stained for 30 min at room temperature with 50 ll 0.4%
SRB dissolved in 1% acetic acid. The wells were then washed
4 times with 1% acetic acid. The plates were air-dried and the
dye was solubilized with 100 ll/well of 10 mM tris base (ph
10.5) for 5 min on a shaker (Orbital shaker OS 20, Boeco,
Germany) at 1600 rpm. The optical density (O.D.) of each
well was measured spectrophotometrically at 564 nm with
an ELIZA microplate reader (Meter tech. R 960, U.S.A.).
The mean background absorbance was automatically sub-
tracted. The percentage of cell survival was calculated as
follows:
Survival fraction ¼ O:D:ðtreatedcellsÞ=O:D:ðcontrolcellsÞ:
IC50 values are the concentrations of thymoquinone required
to produce 50% inhibition of cell growth. The experiment was
repeated 3 times for each cell line.1.22.5. In vivo anti-tumor activity
As tumors reached the desired volume (0.3–0.6 cm3) treatment
was started. Sixty mice were initially used and randomly
divided into four groups A, B, C and D. The treatment groups
(A, B and C) were intravenously given a single dose injection
of DOX loaded liposomes (2.5 mg/kg, 1.36 mg/kg) and DOX
(2.5 mg/kg) respectively. Mice of group D were injected with

















Figure 1 Dose dependent cytotoxicity of free DOX (d) and
DOX loaded liposomes (n) in HCT-15 cell line. The growth
inhibition was measured two days post treatment. The inhibition
was calculated with respect to control. Data were expressed as
mean ± S.E.2.6. Tumor size measurements
Due to the high growth rate in Ehrlich tumor model, change in
tumor volume (DV) was monitored over 21-day period for
the four groups A, B, C and D. Ellipsoidal tumor volume
(V) was assessed every three days and calculated using the
formula:
V ¼ ðp=6ÞðdÞ2ðDÞ
(Montgomery et al., 2000; Ogawara et al., 2009; Elbialy
et al., 2010) where D and d are the long and short axes,
respectively measured with a digital caliper (accuracy
0.01 mm). Fisher’s LSD (least signiﬁcance difference) multi-
ple-comparison test was conducted to check the signiﬁcance
between group pairs. SPSS version 17 was used for statisti-
cal analysis.2.7. Histopathological examination
Three days post injection, 2 mice of the treated groups A, B
and C were sacriﬁced in order to investigate the tumor cell
necrotic percentage. Tumors were excised, ﬁxed in 10% neutral
formalin, embedded in parafﬁn blocks and sectioned. Tissue
sections were stained with hematoxylin and eosin (H&E).
The previous procedures were repeated for control group D.
All tissue sections were examined using light microscope
(CX31 Olympus microscope) connected with a digital camera
(Canon).
3. Results and discussion
The efﬁcacy of drug delivery system has been assessed in vitro
using cell viability assay (SBR assay). The cytotoxicity of free
DOX and DOX loaded liposomes on HCT-15 colon cancer
cell line has been measured. Compared with free drug, the syn-
thesized Dox liposomes exhibit remarkable cytotoxicity. Two
days post drug application, the IC50 values of free drug and
DOX loaded liposomes formulation were 4.5 lg/ml and
35.5 lg/ml, respectively, (Fig. 1). For free doxorubicin treated
cells, the percentage of cell viability decreased as the drug con-
centration increased. This is due to the anticancer effect of
doxorubicin. For DOX loaded liposome treated cells, the
marked increase in the IC50 value may be attributed to the sus-
tained release of doxorubicin from liposomes. So, as the con-
centration of the encapsulated drug increases, the amounts
of released drug also increase and consequently the cell viabil-
ity decreases when the encapsulated drug concentration
increases.
An important site of cytotoxic action of the anticancer drug
doxorubicin is the nucleus, where doxorubicin intercalates into
DNA, forming DNA adducts and inhibiting topoisomerase II
(Gewirtz, 1999). When free doxorubicin reaches the tumor site,
doxorubicin that is released from liposomes within the tumor
interstitial space is capable of diffusing widely within the
tumor. Doxorubicin can diffuse into surrounding cell
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compartments such as mitochondria and nuclei.
DPPG is a lipid with high phase transition temperature and
can increase the rigidity of the bilayer. It has also negative
charges that can bind electrostatically with the positive charges
of doxorubicin. Cholesterol condenses the acyl chains of
DMPC above the phase transition temperature due to an inter-
action between cholesterol and the acyl chains of the phospho-
lipid molecules (Ghannam et al., 1999; Mady, 2007). The
limited freedom of acyl chains causes the membrane to con-
dense, with a reduction in area, closer packing and decreased
ﬂuidity (Ghannam et al., 1999; Mady, 2007).
The efﬁcacy of the drug delivery system used in this study
has been assessed in vivo by following up the change in Ehrlich
tumor volume over 21-day period for the four groups (Fig. 2).
Under our experimental conditions, a pronounced inhibition
in tumor growth was demonstrated in the DOX loaded lipo-
somes treated groups A and B. Such marked decrease in Ehr-
lich tumor volume upon treatment was attributed to antitumor
activity of the encapsulated doxorubicin. The accumulation of
DOX loaded liposomes within Ehrlich tumor cells was due to
the enhanced permeability and retention (EPR) of tumor vas-
culature. Moreover, DOX loaded liposomes destabilized in
slightly acidic environment of tumor, resulting in triggered
DOX release. While for treated group C administrated with
free DOX, a slight inhibition in tumor volume up to day 6
was observed. Then, the tumors began to grow slowly at day
9 when compared with that of control group D. This result
would be attributed to the rapid elimination of free DOX solu-
tion from plasma by being excreted into bile and urine and as a
consequence the amount of DOX delivered to tumor tissues
was quite low (Fig. 2). Control group D showed a marked
increase in tumor volume (growth) with time (Fig. 2).
Statistical analysis clearly demonstrated that the adminis-
trated two DOX loaded liposome formulations, in the treated
groups A and B, have a high signiﬁcant suppression effect on
tumor growth rate up to 21 days with signiﬁcant p-values of



















Figure 2 The average changes in Ehrlich tumor volume as a
function of time for the three treated groups A, B, C and untreated
group D throughout a period of 21 days.not statistically observed in group C compared with group D
during the same period.
DOX-loaded liposomes have enhanced efﬁcacy in some
solid tumors compared with free doxorubicin, because they
passively target solid tumors through the enhanced permeabil-
ity and retention effect (Maeda et al., 2000, 2001), resulting in
increased drug payloads delivered to tumors. The enhanced
permeability and retention effect are a result of defective vas-
cular endothelial linings of growing tumors, resulting in gaps
in the endothelium up to f800 nm in diameter, which are large
enough to permit the extravasation of liposomes with diame-
ters in the range of 100 nm (Ishida et al., 1999). In addition,
growing tumors have defective lymphatic drainage, which con-
tributes to the extended residence time of extravasated lipo-
somes in the interstitial space of the tumor. Liposomes
residing in the interstitial space gradually release their
entrapped drug, exerting antitumor effects.
Histopathological examinations conﬁrmed the observed
inhibition of tumor growth rate for treated groups in addition
to the high growth rate of the control group. Examination of
the entire tumor sections for the various groups revealed
marked differences in cellular features accompanied by varying
degrees in necrosis percentage. Fig. 3 (a–d) shows a histopa-
thological examination for the four experimental mice groups
using a light microscope. The images show tumor tissue sec-
tions excised from mice of group D (Fig. 3a), group C
(Fig. 3b), group B (Fig. 3c) and group A (Fig. 3d). The calcu-
lated necrotic percentages for the experimental groups A, B, C,
and D were 12%, 45%, 65% and 70%, respectively. Control
group (D) showed tissue architectural disarray, as well as
marked degree of cellular anaplasia, pleomorphism and aniso-
cytosis, with nuclear dyschromasia. Also giant form is encoun-
tered, at the upper right ﬁeld, with multiple atypical nuclei.
Additionally, minimum necrosis was revealed at the lower ﬁeld
with a necrosis percent of about 12 (mean ﬁeld count)
(Fig. 3a). For free doxorubicin treated group C, microscopic
examination revealed an increase in necrosis percent up to
40–45% with nodules of viable round cell inﬁltrate surrounded
by ghosts of degenerated cells (Fig. 3b). For treated group B,
microscopic examination revealed sheets of round cell inﬁltrate
admixed with red necrotic areas with ghosts of degenerated
cells representing about 65% of tumor area (Fig. 3c). Treated
group A that has the highest necrosis percent showed a com-
plete loss of cellular details ‘‘ghosts’’ leaving only island of
tumor viability with mean ﬁeld count 70% (Fig. 3d).
Based on the results obtained in the present study, the fol-
lowing mechanisms may be behind the anti-tumor effects of
DOX loaded liposomes recognized in tumor bearing mice.
First, the PEG liposome in the blood circulation gradually
extravasated into the interstitial space of the tumor tissue
due to EPR effect as reported previously (Maeda et al.,
2000; Iyer et al., 2006; Northfelt et al., 1998; Schmidt et al.,
1998). Therefore, DOX encapsulated in the liposome must
be ﬁrst released into the interstitial space of the tumor to be
taken up by the tumor cells via passive diffusion. This specula-
tion was supported by the facts that PEG liposomal DOX
exhibited very large value of IC50 in control mice because
these results reﬂect that cytotoxic effect would be dependent
on DOX slowly released out of the PEG liposome. In the case
of control tumor, DOX passively taken up by control would
have exerted its anti-tumor activity against the tumor cells
directly, leading to the apoptosis of tumor cells throughout
Figure 3 Sections of Ehrlich tumor tissues excised, 21 days post treatment, from mice of (a) control group D, (b) treated group C (free
doxorubicin), (c) treated group B (DOX loaded liposomes 2.5 mg/kg) and (d) treated group A (DOX loaded liposomes 1.36 mg/kg).
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taken up by Ehrlich tumor would have been subjected to the
efﬂux out of the cells, which would have led to the much less
apoptotic cell death in the tumor (Figs. 2 and 3). Subsequently,
the resultant larger amount of DOX accumulated in the inter-
stitial space of the tumor tissue would have penetrated into the
neighboring vascular endothelial cells.
It is clear that the preparation of such nano-sized DOX
loaded liposomal formulation facilitate their passive targeting
to the tumor. In addition to their successful accumulation
inside tumor tissues due to the enhanced permeability and
retention effect (EPR) which slow down their lymphatic drain-
age and providing a prolonged time of circulation in blood
over free DOX solution. All the above mentioned factors pro-
mote the use of such formulations as an efﬁcient oncological
modality over the other traditional chemotherapeutic agents.4. Conclusion
The proposed liposomal formulation can efﬁciently deliver the
drugs into the tumor cells by endocytosis (or passive diffusion)
and lead to a high concentration of DOX in the tumor cells.
Administration of these DOX loaded liposomes to tumor-
bearing mice could be used to deliver DOX effectively to the
targeted site, signiﬁcantly increasing the DOX content in
tumor. This would improve the therapeutic index of DOX,
and is a proof of principle in support of administering liposo-
mally co-encapsulated drug. Based on the results in this study,
it is suggested that the proposed liposomal formulation could
be employed to enhance the intracellular delivery of anticancer
agents such as cytotoxic drugs, antisense nucleic acids and
ribozymes or imaging agents.References
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